ECD-Score: a Study on Erdheim-Chester Disease

Key facts

Sponsor

Meyer Children's Hospital IRCCS

Principal Investigator

Augusto Vaglio, Medical Doctor

Meyer Children's Hospital IRCCS

Enrollment

1000 enrolled

Eligibility

7 years · All sexes

Timeline

2024 – 2028

Study locations (7)

• National Institute of Health, Bethesda, Maryland, United States
• Mayo Clinic, Rochester, Minnesota, United States
• Memorial Sloan Kettering Cancer Center, New York, New York, United States
• Hopital Pitiè-Salpetriere, Paris, France
• Meyer Children's Hospital IRCCS, Firenze, Florence, Fi, Italy
• San Raffaele Hospital, Milan, Italy, Italy
• Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle, Newcastel, United Kingdom

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Erdheim-Chester disease

Additional recruiting or active studies for the same condition.

• RECRUITINGNCT05915208
  Histiocytic Disorder Follow-up Study
  University of Alabama at Birmingham
• RECRUITINGEARLY PHASE1NCT05093335
  In-Human CXCR4 Imaging of Hematologic and Solid Tumors Using [68Ga]-Pentixafor-PET
  Memorial Sloan Kettering Cancer Center
• RECRUITINGPHASE2NCT04079179
  Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders
  Carl Allen
• RECRUITINGNCT03990428
  Supportive Care Needs of Caregivers of People With Erdheim-Chester Disease and Other Histiocytic Diseases
  Memorial Sloan Kettering Cancer Center
• RECRUITINGNCT03329274
  Registry for Patients With Erdheim-Chester Disease and Other Histiocytoses
  Memorial Sloan Kettering Cancer Center
• ACTIVE NOT RECRUITINGPHASE2NCT02523040
  Lenalidomide for Adult Histiocyte Disorders
  Dana-Farber Cancer Institute
• RECRUITINGNCT02285582
  International Rare Histiocytic Disorders Registry (IRHDR)
  The Hospital for Sick Children

See all trials for Erdheim-Chester disease →